The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 23, 2019

Filed:

Oct. 07, 2016
Applicant:

Metabolon, Inc., Durham, NC (US);

Inventors:

Michael V. Milburn, Cary, NC (US);

John A. Ryals, Chapel Hill, NC (US);

Lining Guo, Chapel Hill, NC (US);

Andrea Eckhart, Durham, NC (US);

Jacob Wulff, Morrisville, NC (US);

Adam D. Kennedy, Durham, NC (US);

Thomas J. Jönsson, Durham, NC (US);

Ryan Douglas Michalek, Durham, NC (US);

Bryan Wittmann, Rougemont, NC (US);

Matthew Mitchell, Durham, NC (US);

Assignee:

Metabolon, Inc., Morrisville, NC (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 30/72 (2006.01); G01N 30/88 (2006.01); G01N 33/50 (2006.01); H01J 49/00 (2006.01); G01N 33/487 (2006.01);
U.S. Cl.
CPC ...
G01N 30/88 (2013.01); G01N 30/7206 (2013.01); G01N 30/7233 (2013.01); G01N 33/487 (2013.01); G01N 33/50 (2013.01); H01J 49/0036 (2013.01); G01N 2030/8813 (2013.01); G01N 2800/00 (2013.01); G01N 2800/04 (2013.01); G01N 2800/52 (2013.01);
Abstract

Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.


Find Patent Forward Citations

Loading…